Hanmi Pharmaceuticals, led by CEO Jae-Hyun Park, unveiled groundbreaking research findings at the European Society for Clinical Nutrition and Metabolism (ESPEN) Congress 2023 in Lyon, France, held from August 11th to 14th. The research showcased their innovative short bowel syndrome treatment, 'LAPSGLP-2 analog (development code name HM15912),' administered once a month. Additionally, they introduced a promising potential treatment for Graft Versus Host Disease (GVHD) utilizing HM15912, focusing on its capacity to promote intestinal growth and reduce intestinal inflammation.

GVHD, a severe condition where lymphocytes from a bone marrow transplant attack patients with compromised immune systems, has a high mortality rate and various complications. The current standard treatment involves steroids, alone or in combination with immunosuppressive drugs; however, these treatments have limitations in their effectiveness.

The study revealed significant enhancements in the "GVHD score" and survival rates when HM15912 was administered both preventatively and therapeutically in a GVHD animal model. Moreover, HM15912's protective and regenerative effects on the gastrointestinal tract showed promise in mitigating gastrointestinal complications, a leading cause of death in GVHD. In a separate study, HM15912 exhibited improvements in both GVHD scores and survival rates in animal models that did not respond well to steroids.

A representative from Hanmi Pharmaceuticals emphasized the company's commitment to rare disease treatments, recognizing the considerable suffering endured by patients and their families. Through innovative drug development that presents a new treatment paradigm, they pledge to make a significant contribution to the lives of rare disease patients.